| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Rega Institute for Medical Research, Laboratory of Molecular Immunology, and
Zoological Institute, University of Leuven, Leuven, Belgium
Chemokines are important mediators in infection and inflammation. The monocyte chemotactic proteins (MCPs) form a subclass of structurally related C-C chemokines. MCPs select specific target cells due to binding to a distinct set of chemokine receptors. Recombinant and synthetic MCP-1 variants have been shown to function as chemokine antagonists. In this study, posttranslationally modified immunoreactive MCP-1 and MCP-2 were isolated from mononuclear cells. Natural forms of MCP-1 and MCP-2 were biochemically identified by Edman degradation and mass spectrometry and functionally characterized in chemotaxis and Ca2+-mobilization assays. Glycosylated MCP-1 (12 and 13.5 kDa) was found to be two- to threefold less chemotactic for monocytes and THP-1 cells than nonglycosylated MCP-1 (10 kDa). Natural, NH2-terminally truncated MCP-1(5–76) and MCP-1(6–76) were practically devoid of bioactivity, whereas COOH-terminally processed MCP-1(1–69) fully retained its chemotactic and Ca2+-inducing capacity. The capability of naturally modified MCP-1 forms to desensitize the Ca2+ response induced by intact MCP-1 in THP-1 cells correlated with their agonistic potency. In contrast, naturally modified MCP-2(6–76) was devoid of activity, but could completely block the chemotactic effect of intact MCP-2 as well as that of MCP-1, MCP-3, and RANTES. Carboxyl-terminally processed MCP-2(1–74) did retain its chemotactic potency. Although comparable as a chemoattractant, natural intact MCP-2 was found to be 10-fold less potent than MCP-1 in inducing an intracellular Ca2+ increase. It can be concluded that under physiologic or pathologic conditions, posttranslational modification affects chemokine potency and that natural MCP-2(6–76) is a functional C-C chemokine inhibitor that might be useful as an inhibitor of inflammation.
This article has been cited by other articles:
|
|
 |
|
  M. Rafei, Y. A. Berchiche, E. Birman, M.-N. Boivin, Y. K. Young, J. H. Wu, N. Heveker, and J. Galipeau An Engineered GM-CSF-CCL2 Fusokine Is a Potent Inhibitor of CCR2-Driven Inflammation As Demonstrated in a Murine Model of Inflammatory Arthritis J. Immunol., August 1, 2009; 183(3): 1759 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rafei, P. M. Campeau, A. Aguilar-Mahecha, M. Buchanan, P. Williams, E. Birman, S. Yuan, Y. K. Young, M.-N. Boivin, K. Forner, et al. Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner J. Immunol., May 15, 2009; 182(10): 5994 - 6002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction Blood, December 15, 2008; 112(13): 4991 - 4998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Proost, T. Loos, A. Mortier, E. Schutyser, M. Gouwy, S. Noppen, C. Dillen, I. Ronsse, R. Conings, S. Struyf, et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation J. Exp. Med., September 1, 2008; 205(9): 2085 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hori, Y. Naishiro, H. Sohma, N. Suzuki, N. Hatakeyama, M. Yamamoto, T. Sonoda, Y. Mizue, K. Imai, H. Tsutsumi, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease Blood, April 15, 2008; 111(8): 4403 - 4412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Coppinger, R. O'Connor, K. Wynne, M. Flanagan, M. Sullivan, P. B. Maguire, D. J. Fitzgerald, and G. Cagney Moderation of the platelet releasate response by aspirin Blood, June 1, 2007; 109(11): 4786 - 4792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van der Voort, M. Kramer, E. Lindhout, R. Torensma, D. Eleveld, A. W. T. van Lieshout, M. Looman, T. Ruers, T. R. D. J. Radstake, C. G. Figdor, et al. Novel monoclonal antibodies detect elevated levels of the chemokine CCL18/DC-CK1 in serum and body fluids in pathological conditions J. Leukoc. Biol., May 1, 2005; 77(5): 739 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Kyriakides, M. J. Foster, G. E. Keeney, A. Tsai, C. M. Giachelli, I. Clark-Lewis, B. J. Rollins, and P. Bornstein The CC Chemokine Ligand, CCL2/MCP1, Participates in Macrophage Fusion and Foreign Body Giant Cell Formation Am. J. Pathol., December 1, 2004; 165(6): 2157 - 2166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Strasly, G. Doronzo, P. Capello, D. Valdembri, M. Arese, S. Mitola, P. Moore, G. Alessandri, M. Giovarelli, and F. Bussolino CCL16 activates an angiogenic program in vascular endothelial cells Blood, January 1, 2004; 103(1): 40 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sasaki, H. Hasegawa, M. Kohno, A. Inoue, M. R. Ito, and S. Fujita Antagonist of Secondary Lymphoid-Tissue Chemokine (CCR Ligand 21) Prevents the Development of Chronic Graft-Versus-Host Disease in Mice J. Immunol., January 1, 2003; 170(1): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hale-Donze, T. Greenwell-Wild, D. Mizel, T. M. Doherty, D. Chatterjee, J. M. Orenstein, and S. M. Wahl Mycobacterium avium Complex Promotes Recruitment of Monocyte Hosts for HIV-1 and Bacteria J. Immunol., October 1, 2002; 169(7): 3854 - 3862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. McQuibban, J.-H. Gong, J. P. Wong, J. L. Wallace, I. Clark-Lewis, and C. M. Overall Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo Blood, July 30, 2002; 100(4): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Dumont, S. Dremier, I. Pirson, and C. Maenhaut Cross signaling, cell specificity, and physiology Am J Physiol Cell Physiol, July 1, 2002; 283(1): C2 - C28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Schutyser, S. Struyf, P. Proost, G. Opdenakker, G. Laureys, B. Verhasselt, L. Peperstraete, I. Van de Putte, A. Saccani, P. Allavena, et al. Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma J. Biol. Chem., June 28, 2002; 277(27): 24584 - 24593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Valenzuela-Fernandez, T. Planchenault, F. Baleux, I. Staropoli, K. Le-Barillec, D. Leduc, T. Delaunay, F. Lazarini, J.-L. Virelizier, M. Chignard, et al. Leukocyte Elastase Negatively Regulates Stromal Cell-derived Factor-1 (SDF-1)/CXCR4 Binding and Functions by Amino-terminal Processing of SDF-1 and CXCR4 J. Biol. Chem., May 3, 2002; 277(18): 15677 - 15689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Lee, E. H. Lee, Y. P. Yun, K. Kim, K. Kwack, D. S. Na, B. S. Kwon, and C.-K. Lee Truncation of NH2-terminal Amino Acid Residues Increases Agonistic Potency of Leukotactin-1 on CC Chemokine Receptors 1 and 3 J. Biol. Chem., April 19, 2002; 277(17): 14757 - 14763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Proost, E. Schutyser, P. Menten, S. Struyf, A. Wuyts, G. Opdenakker, M. Detheux, M. Parmentier, C. Durinx, A.-M. Lambeir, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties Blood, December 15, 2001; 98(13): 3554 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yoshida, S. G Elner, Z.-M. Bian, and V. M Elner Induction of interleukin-8 in human retinal pigment epithelial cells after denuding injury Br J Ophthalmol, July 1, 2001; 85(7): 872 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Van den Steen, P. Proost, A. Wuyts, J. Van Damme, and G. Opdenakker Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact Blood, October 15, 2000; 96(8): 2673 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. King, K. Johanson, C. L. Frey, P. L. DeMarsh, J. R. White, P. McDevitt, D. McNulty, J. Balcarek, Z. L. Jonak, P. K. Bhatnagar, et al. Identification of Unique Truncated KC/GRO{beta} Chemokines with Potent Hematopoietic and Anti-Infective Activities J. Immunol., April 1, 2000; 164(7): 3774 - 3782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. B. Nibbs, T. W. Salcedo, J. D. M. Campbell, X.-T. Yao, Y. Li, B. Nardelli, H. S. Olsen, T. S. Morris, A. E. I. Proudfoot, V. P. Patel, et al. C-C Chemokine Receptor 3 Antagonism by the {beta}-Chemokine Macrophage Inflammatory Protein 4, a Property Strongly Enhanced by an Amino-Terminal Alanine-Methionine Swap J. Immunol., February 1, 2000; 164(3): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Burns, G. K. Lewis, and A. L. DeVico Soluble complexes of regulated upon activation, normal T cells expressed and secreted (RANTES) and glycosaminoglycans suppress HIV-1 infection but do not induce Ca2+ signaling PNAS, December 7, 1999; 96(25): 14499 - 14504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Struyf, P. Proost, S. Sozzani, A. Mantovani, A. Wuyts, E. De Clercq, D. Schols, and J. Van Damme Cutting Edge: Enhanced Anti-HIV-1 Activity and Altered Chemotactic Potency of NH2-Terminally Processed Macrophage-Derived Chemokine (MDC) Imply an Additional MDC Receptor J. Immunol., September 15, 1998; 161(6): 2672 - 2675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lee, J. Rucker, R. W. Doms, M. Tsang, X. Hu, M. Dietz, R. Bailer, L. J. Montaner, C. Gerard, N. Sullivan, et al.  -Chemokine MDC and HIV-1 InfectionScience, July 24, 1998; 281(5376): 487a - 487. [Full Text]
|
|
|
|
|
|
J. R. Townson, G. J. Graham, N. R. Landau, B. Rasala, and R. J. B. Nibbs Aminooxypentane Addition to the Chemokine Macrophage Inflammatory Protein-1alpha P Increases Receptor Affinities and HIV Inhibition J. Biol. Chem., December 8, 2000; 275(50): 39254 - 39261. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
